Intervention not reported
False‐positives (participants incorrectly classified as having TB meningitis)
1 finding from 1 review
Intervention not reported
Xpert MTB/RIF result
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Xpert Ultra result
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
True‐positives (patients with pleural TB)
1 finding from 1 review
Intervention not reported
False‐negatives (patients incorrectly classified as not having pleural TB)
1 finding from 1 review
Intervention not reported
Index test, population · people living with HIV and non‐hospitalized people in high‐risk groups
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Xpert MTB/RIF, people living with HIV · people living with HIV and non‐hospitalized people in high‐risk groups
1 finding from 1 review
Intervention not reported
Xpert Ultra, people living with HIV · people living with HIV and non‐hospitalized people in high‐risk groups
1 finding from 1 review
Intervention not reported
Xpert MTB/RIF, non‐hospitalized people in high‐risk groups · people living with HIV and non‐hospitalized people in high‐risk groups
1 finding from 1 review
Intervention not reported
Index test · people in high‐risk groups
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Xpert MTB/RIF · people in high‐risk groups
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly showed no clear difference in active TB compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher adherence compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly leads to lower hepatotoxicity compared with isoniazid daily (high certainty).
1 finding from 1 review